Unknown

Dataset Information

0

IRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer.


ABSTRACT: Poor infiltration of activated lymphocytes into tumors represents a fundamental factor limiting the therapeutic effect of adoptive cell immunotherapy. A tumor-penetrating peptide, iRGD, has been widely used to deliver drugs into tumor tissues. In this study, we demonstrate for the first time that iRGD could also facilitate the infiltration of lymphocytes in both 3D tumor spheroids and several xenograft mouse models. In addition, combining iRGD modification with PD-1 knockout lymphocytes reveals a superior anti-tumor efficiency. Mechanistic studies demonstrate that the binding of iRGD to neuropilin-1 results in tyrosine phosphorylation of the endothelial barrier regulator VE-cadherin, which plays a role in the opening of endothelial cell contacts and the promotion of transendothelial lymphocyte migration. In summary, these results demonstrate that iRGD modification could promote tumor-specific lymphocyte infiltration, and thereby overcome the bottleneck associated with adoptive immune cell therapy in solid tumors.

SUBMITTER: Ding N 

PROVIDER: S-EPMC6430780 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer.

Ding Naiqing N   Zou Zhengyun Z   Sha Huizi H   Su Shu S   Qian Hanqing H   Meng Fanyan F   Chen Fangjun F   Du Shiyao S   Zhou Shujuan S   Chen Hong H   Zhang Lianru L   Yang Ju J   Wei Jia J   Liu Baorui B  

Nature communications 20190322 1


Poor infiltration of activated lymphocytes into tumors represents a fundamental factor limiting the therapeutic effect of adoptive cell immunotherapy. A tumor-penetrating peptide, iRGD, has been widely used to deliver drugs into tumor tissues. In this study, we demonstrate for the first time that iRGD could also facilitate the infiltration of lymphocytes in both 3D tumor spheroids and several xenograft mouse models. In addition, combining iRGD modification with PD-1 knockout lymphocytes reveals  ...[more]

Similar Datasets

| S-EPMC10530473 | biostudies-literature
| S-EPMC9235886 | biostudies-literature
| S-EPMC6410779 | biostudies-literature
| S-EPMC8770548 | biostudies-literature
| S-EPMC7298268 | biostudies-literature
| S-EPMC10582428 | biostudies-literature
| S-EPMC8656870 | biostudies-literature
| S-EPMC3864274 | biostudies-literature
| S-EPMC9714418 | biostudies-literature
| S-EPMC9520605 | biostudies-literature